Skip to Main Content

Paper Details

Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.
Oncotarget
19
2016
2341luc, 2341luc engraftment model, 2341luc tumor, Akt, BRAFV600E, BRAFV600E glioma, BRAFV600E kinase, BrafV600E, BrafV600E mutant and, Cdkn2a, MAPK, MAPK kinase, MEK, dabrafenib, glioma, high-grade glioma, high-grade glioma-like tumors, intracranial, luciferase, luciferase-modified cell line, melanoma, mice, mitogen-activated protein kinase, murine, patients, trametinib, tumor, tumor cells, tumors
Author NameAffiliation
Nathalène TruffauxBrain Tumor Research Center
Theodore NicolaidesBrain Tumor Research Center
Theodore NicolaidesUniversity of California San Francisco
Mitchel S BergerBrain Tumor Research Center
Mitchel S BergerBrain Tumor Research Center
Joanna J PhillipsBrain Tumor Research Center
Joanna J PhillipsBrain Tumor Research Center
Charles D JamesFeinberg School of Medicine, Northwestern University
Claudia PetritschBrain Tumor Research Center
Claudia PetritschHelen Diller Comprehensive Cancer Research Center, University of California San Francisco
Claudia PetritschUniversity of California San Francisco
  • 1 - 11

Datasets

Release 1.2